Ocular hypotensive effects of the ATP sensitive potassium channel opener cromakalim in human and murine experimental model systems

Keyphrases

• Additive Effect 14%
• Anterior Segment 28%
• Aqueous Humor Outflow 14%
• ATP-sensitive Potassium Channel Opener 100%
• C57BL 14%
• Cell number 14%
• Channel Subunits 14%
• Contralateral Eye 14%
• Cromakalim 100%
• Current Therapeutics 14%
• Elevated Intraocular Pressure 42%
• Experimental Model Systems 100%
• Extracellular Matrix 14%
• Free Acid 14%
• Future Therapeutics 14%
• Glaucoma 28%
• Glaucoma Medication 14%
• Histological Analysis 14%
• Human Experimental Models 100%
• Hypotensive Agents 14%
• In Vivo murine Model 100%
• Inner Wall 14%
• Intraocular Pressure 42%
• Irreversible Blindness 14%
• KATP Channel 28%
• KATP Channel Opener 14%
• Kir6.2 28%
• Latanoprost 28%
• Low Intraocular Pressure 14%
• Matrix Integrity 14%
• Ocular Hypotension 100%
• Ocular Hypotensive Drugs 14%
• Outer Wall 14%
• Outflow Pathway 14%
• Risk Factors 14%
• Schlemm's Canal 14%
• Therapeutic Development 14%
• Trabecular Meshwork 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Adenosine Triphosphate Sensitive Potassium Channel 42%
• Antihypertensive Agent 14%
• ATP-Sensitive Potassium Channel Opener 100%
• C57BL 6 Mouse 14%
• Channel Opener 14%
• Cromakalim 100%
• Glaucoma 42%
• Latanoprost 28%
• Ocular Hypotensive Agent 14%
• Side Effect 14%